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Abstract: We investigated the effect of ATP-MgCl2 on myocardial hemodynamics and ultrastructure.
In the in vitro study, left ventricular systolic and diastolic pressures and dp/dt values were significantly high in the ATP-MgCl2 group
beginning from 0.5 h of the reperfusion period. In the ATP-MgCl2 group, at the end of the third hour, systolic and diastolic pressure
values were 80.0 ± 6.2 and 75.2 ± 7.2 mmHg, while in the control group they were 18.4 ± 7.7 and 7.5 ± 6.8 mmHg (P < 0.05).
In the ultrastructural analysis, myofibrillary damage was observed in both groups, but the mitochondrial pathologic changes were
clearer in the control group. The electron microscopic score was 0.40 ± 0.061 in the ATP-MgCl2 group and 1.2 ± 0.039 in the
control group (P < 0.001).
The hemodynamic and ultrastructural parameters of the specimens investigated in this study revealed that the usage of ATP-MgCl2
may be beneficial in coping with ischemia-reperfusion damage. In the near future, with the help of more comprehensive studies,
ATP-MgCl2 is expected to be used routinely because of its potential benefits.
Key Words: In vitro perfusion, ischemia-reperfusion damage, myocardium, ATP-MgCl2

‹skemi-Reperfüzyon Döneminde ATP-MgCl2 Kullan›m›n›n Myokardiyal
Düzelmeye Etkisi; ‹n Vitro Çal›flma
Özet: Bu çal›flmada iskemi-reperfüzyon hasar›nda ATP-MgCl2 kullan›m›n›n myokard üzerine etikisi hemodinamik ve ultrastrüktürel
parametreler yard›m› ile araflt›r›ld›.
‹n vitro perfüzyon çal›flmas›nda; sol ventrikül sistolik ve diastolik bas›nçlar› ve dp/dt de¤erleri reperfüzyon ölçümlerinin 0,5 saatinden
bafllayarak anlaml› flekilde ATP-MgCl2 grubunda kontrol grubuna göre yüksek bulunmufltur. ATP-MgCl2 grubunda 3. saatin sonunda
sistolik ve diastolik bas›nç de¤erleri 80,0 ± 6,2 mmHg ve 75,2 ± 72 mmHg, kontrol grubunda ise 18,4 ± 7,7 mmHg ve 7,5 ± 6,8
mmHg idi (P < 0,05). Dokular›n analizinde, her iki grup da da myofibriller yap›da hasar gözlendi. Ancak kontrol grubunda
mitokondrial patoloji belirgin olup ATP-MgCl2 grubunda hemen hemen normale yak›nd›. Elektron mikroskobik skor kontrol
grubunda 1,2 ± 0,039, ATP-MgCl2 grubunda 0,40 ± 0,061 olarak hesapland› (P < 0,001).
Bu çal›flma sonucunda; ATP-MgCl2 kullan›m› gerçeklefltirilen iskemi-reperfüzyon yaralanmalar›nda, ultrastrüktürel analizlerin
incelenmesi sonucunda hemodinamik ve ultrastrüktürel parametrelerin düzeltmesi aç›s›ndan faydal› bulunmufltur. Bu çal›flmay› takip
edecek daha kapsapl› ve ileri çal›flmalar›n yap›lmas› ile ATP-MgCl2 ‘ün faydal› bir ilaç olma olas›l›¤› kaç›n›lmazd›r.
Anahtar Sözcükler: ‹n vitro perfüzyon, iskemi-reperfüzyon hasar›, myokard, ATP-MgCl2

* This research was supported by TÜB‹TAK VHAG and was carried out in the Experimental Surgery Research Centre, which was established in 1998
under the authority of Ankara University Veterinary Faculty Surgical Department. Project number: DECAR 4.
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Introduction
Although knowledge concerning heart surgery has
advanced, studies dealing with myocardial protection are
still crucial. It is not possible to monitor all the events
happening in cells during ischemia-reperfusion, especially
those related with their functions and dysfunctions (1).
In addition to such myocardial protection techniques
as hypothermia and crystalloid cardioplegia, which have
been proved to be effective, studies have attempted to
develop the ideal myocardial protection using retrograde
cardioplegia infusion through the coronary sinus, cold and
warm blood-cardioplegia, simultaneous antegrade and
retrograde continuous cold blood cardioplegia and several
pharmacological protective substances (2-5).
Magnesium is a necessary co-factor for both effective
energy usage and enzymatic reactions. These enzymatic
reactions include the following: mitochondrial functions,
provision of necessary energy for transsarcolemmal ionic
gradients, control of cell volume, and maintaining the
resting membrane potential (6). Magnesium is essential
for regular function of the Na-K ATPase pump. It
regulates the potassium balance in the cell. Moreover,
calcium ATPase and proton pumps need magnesium (610).
In studies investigating myocardial metabolism and
hemodynamics, several distinct models and test animals
have been used. Of these models, the most commonly
used one is the isolated perfused heart model
(Langendorff). Since its introduction in 1895, it has been
modified and is considered the most preferred model
worldwide. In this system, the heart is perfused at a
certain pressure or flow level from the aorta
retrogradely. Closing of the aortic leaflets as a result of
the perfusion enables all perfusate to reach the coronary
arteries (11).
ATP depots begin to decrease quickly in a 3-4 min
interval following the ischemia. As a result of this
decrease, oxidative phosphorilation completely stops.
Thus, intracellular ion homeostasis is corrupted, and this
leads to cell injury. Lipid peroxidation, which occurs as a
result of free oxygen radicals formed during the
reperfusion period following ischemia, causes damage to
the cell membrane and microvascular spasms (12-14).
Magnesium treatment has been used in various
cardiovascular diseases such as myocardial infarction and
450

arrhythmias. Furthermore, decreases in intracellular or
extracellular magnesium levels may lead to hypertension,
congestive heart failure, and arrhythmias related to
myocardial infarction (15,16).
Intracellular magnesium prevents deficiencies in
potassium and high-energy phosphates in the cell. It may
also prevent intracellular overloading of calcium and
sodium. Decreasing the metabolic activity and calcium
entrance, magnesium indirectly regulates the cellular
free-energy level (15). High levels of magnesium improve
intracellular ATP production and glucose usage.
Magnesium is known as a physiological calcium blocker
and it protects the cells from calcium overload during
ischemia (17).
Pearson et al. (18) showed that hypomagnesemia
damages the nitric oxide (NO) release from the coronary
endothelia in a dog model. Hypomagnesemia may
increase vasoconstriction and thrombosis. Dickens et al.
(19) proved that, in the case of magnesium deficiency,
those tissues exposed to oxidative stress are extremely
damaged as a result of cellular lipid peroxidation. In a dog
gracilis-muscle ischemia-reperfusion model, it was
indicated that superoxide release from active neutrophils
can be decreased with ATP-MgCl2 and its protective effect
is partially based on this fact (20). In the case of
magnesium deficiency, oxidative damage is increased
after ischemia as well, and this damage can be avoided
with the help of antioxidants (21).
Magnesium has been investigated for a long time in
relation to organ ischemia and shock. The magnesium
level decreases in ischemic injuries of nerve tissues. This
decrease damages the cell membrane integrity, ATPase
function and particularly the production of co-factors that
play an important role in the production of energy.
Magnesium treatment improves the microcirculatory
dysfunction observed in reperfusion, increases total blood
flow through vital organs and decreases cell edema.
Regulating the calcium transport, magnesium helps to
decrease the tissue damage based on calcium. It raises the
ATP levels, which are depleted during the ischemic period
(22-24).
The present study investigated the effect of ATPMgCl2 on myocardium, using an in vitro perfusion system
with the help of hemodynamic and ultrastructural
parameters.
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Materials and Methods
In the in vitro perfusion study, the model of isolated
Langendorff rabbit heart was employed. This research
was supported by TÜB‹TAK and was carried out in the
Experimental Surgery Research Center, which was
established in 1998 under the authority of Ankara
University Veterinary Faculty Surgical Department.
The study used control and study groups, each
consisting of 6 New Zealand rabbits. The rabbits weighed
2-2.5 kg and they were 2-3 months old. The study was
conducted with the approval of the Ethical Committee of
the same institution.
For 12 h before the research, the rabbits were not
fed. A premedication was applied firstly using atropine
sulfate (0.5 mg/kg) and 10 min later using xylasine
hydrochloride (5 mg/kg). Five minutes after
premedication, anesthesia was achieved intramuscularly
using ketamine hydrochloride (50 mg/kg) and phentanyl
(0.15 mg/kg). After injecting heparin (100 U) through
the vena auricularis magna, median sternotomy was
performed and the pericardium was exposed. Following
pericardiectomy, the aorta and pulmonary artery were
ligated as distally as possible and the heart was taken out.
The heart was immediately put into Krebs solution. The
solution was put into a pot with water (+4 ºC) for
transportation and after that the heart was integrated
into the Langendorff system (Figure 1). The Krebs
solution used for the in vitro perfusion consisted of 118
mmol/l NaCl, 5.4 mmol/l KCl, 1.2 mmol/l MgCl2, 25

mmol/l NaHCO3, 2.4 mmol/l CaCl2, 1 mmol/l Kh2PO4 and
10 mmol/l glucose. A 5% CO2 and 95% O2 gas
combination was also used in the Krebs solution.
The heart, integrated into the Langendorff system, was
perfused for stabilization and adaptation for 20 min. After
the stabilization period, a catheter was placed in the left
ventricle through the left atrium. In this way, left ventricle
pressures and pressure alterations were recorded on a
computer simultaneously using software (MP 100 version
3.2 for Windows, Biopac System, Inc. Santa Barbara CA).
Using the same program, left ventricle pressure diagrams
and its first derivative, dp/dt, were also calculated (Figure
2). After the determination of baseline measurements,
absolute global ischemia was performed for 1 min. During
the next period, the hearts were reperfused for 3 h using
the Krebs solution, which included a gas mixture (5% CO2
and 95% O2), at 37 ºC. The pH level of the solution was
7.35-7.45. The flow rate was 8 ml/min and the heart rate
was 230 beats/min. In the control group, only perfusion
solution was used, while in the study group 30 cc/l ATPMgCl2 was used. ATP-MgCl2 was prepared containing equal
amounts of the 2 elements. ATP, in powder form, was
weighed in 0.9% NaCl solution and the solution amount
was set as 140 µmol/ml. The pH value of the solution was
7.4. Similarly, the solution of MgCl2 was prepared and it
was also 140 µmol/ml. These 2 solutions were equally
mixed. Each milliliter of the solution contained 70 µmol/ml
ATP and MgCl2. Heart rates of the perfused hearts were
stimulated using a computer-controlled stimulator to be
230 beats/min.

Figure 1. Langendorff system.
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intergroup (+) dp/dt values (*P < 0.05).
160

ATPMgCl2

140

All findings were compared using mean ± standard
deviation. The value of P < 0.05 was regarded as the
statistically significant level. In order to analyze the
differences between groups, Student’s t test was used.

Control

120
100
%

Statistical Analysis

80
60
40

Results

20
0

B

P‹ (*)

0.5 s 1 s (*) 1.5 s (*) 2 s (*) 2.5 s (*) 3 s (*)

Figure 2. Values of in vitro perfusion (+) dp / dt.

Ultrastructural Analysis
The samples taken from the left ventricle muscle were
fixed with 2.5% glutaraldehyde. Then they were refixed
with osmium tetraoxide and dehydrated with alcohol
series. Lastly the series were embedded into CY212.
Crosscuts of 60-90 nm were prepared and contrasted
with uranyl acetate. The samples were analyzed using a
JEOL JEM 1200 electron microscope. The pictures were
taken using a Nikon Optiphot microscope. The following
classification method was used to analyze the findings:
Heart scoring for ultrastructural analysis
A. Intracellular edema (scored in 20 areas)
No edema

0

Mild edema

1

Intermediate edema

2

Extreme edema

3

B. Mitochondrial injury (40 mitochondria were scored)
Normal

0

Mild edema

1

Extreme edema

2

C. Glycogen exhaustion (scored in 20 areas)
Completely

0

Slightly

1

Intermediately

2

No glycogen depot

3

D. Myofibrillar structural damage (scored in 20 areas)
Normal I bands

0

Irregular I bands

1

No I bands

2
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In the in vitro study, the left ventricle systolic and
diastolic pressures in the study group (ATP-MgCl2) were
higher than those in the control group beginning from
0.5 h of the reperfusion period. In the ATP-MgCl2 group,
at the end of the third hour, systolic and diastolic
pressure values were 80.0 ± 6.2 and 75.2 ± 7.2 mmHg,
respectively. In the control group these values were 18.4
± 7.7 and 7.5 ± 6.8 mmHg, respectively (P < 0.05)
(Table).
Similarly, between the 2 groups, the values of dp/dt,
which are the first derivative of the left ventricle pressure
values, were different beginning from the start of the
ischemia and such changes lasted until the third hour of
the reperfusion. At the end of the third hour of the
reperfusion period, the levels of change in +dp/dt and
–dp/dt in the ATP-MgCl2 group were 128.4 ± 28.0% and
138.5 ± 9.8%, respectively, in accordance with the
baseline measurements. These values were 73.2 ±
12.6% and 67.6 ± 10.2%, respectively, in the control
group (P < 0.05) (Figures 2 and 3).
Ultrastructural Analysis
In the analysis of the tissue samples of both groups,
no damage in the myofibrillary structure was observed.
However, mitochondrial pathology was evident in the
control group. The mitochondrial structure was almost
regular in the ATP-MgCl2 group. Intracellular edema was
seen in the control group, whereas in the ATP-MgCl2
group significant recovery was observed. The electron
microscopic score was 1.2 ± 0.039 in the control group
and 0.40 ± 0.061 in the ATP-MgCl2 group (P < 0.001)
(Figures 4 and 5).
Discussion
The model of isolated perfusion heart (Langendorff) is
commonly used in studies concerning the myocardial
metabolism and hemodynamics. In this technique, the
heart is perfused at a certain pressure or flow from the
aorta retrogradely (11). Many pharmacological protective
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Table. Hemodynamic values of the in vitro study (*P < 0.05).
ATP-MgCl2 Group
mmHg
Systolic
Diastolic
Mean

Baseline

P. ischemia

0.5 h *

1h*

1.5 h *

2h*

2.5 h *

3h*

30.6 ± 2.6
20.3 ± 2.2
24.4 ± 2.3

32.8 ± 3.1
20.8 ± 1.7
24.6 ± 1.6

61.5 ± 8.5
49.7 ± 10.9
53.6 ± 10.5

82.8 ± 14.4
76.3 ± 15.9
79.2 ± 15.2

85.8 ± 9.9
79.7 ± 11.1
82.6 ± 10.5

86.8 ± 6.9
80.6 ± 8.6
83.5 ± 7.7

85.2 ± 5.6
79.9 ± 7.1
82.5 ± 6.3

80.0 ± 6.2
75.2 ± 7.2
77.6 ± 6.7

Baseline

P. ischemia

0.5 h *

1h*

1.5 h *

2h*

2.5 h *

3h*

28.5 ± 5.9
19.9 ± 6.2
23.3 ± 6.1

29.7 ± 2.1
15.4 ± 6.0
20.9 ± 2.8

24.3 ± 5.2
9.2 ± 3.3
14.3 ± 2.9

18.6 ± 4.7
7.2 ± 3.5
11.8 ± 3.5

22.6 ± 8.5
12.4 ± 6.2
16.8 ± 7.1

18.4 ± 3.7
8.9 ± 4.4
13.2 ± 3.8

24.8 ± 7.3
13.5 ± 7.9
18.4 ± 7.5

18.4 ± 7.7
7.5 ± 6.8
12.4 ± 6.9

Control Group

Systolic
Diastolic
Mean

intergroup (-) dp/dt values (*P < 0.05).

%

mmHg

180
160
140
120
100
80
60
40
20
0

ATPMgCl2
Control

B

P‹ 0.5 s (*) 1 s (*) 1.5 s (*) 2 s (*) 2.5 s (*) 3 s (*)

Figure 3. Values of in vitro perfusion (-) dp / dt.

Figure 4. Electron microscopic view of the sample of in vitro perfusion ATP-MgCl2 group.
a) mitochondrion b) capillary c) nucleus of endothelial cell. d) nucleus of the heart
muscle cell
A slight degeneration in the ultrastructure of heart muscle can be observed. Most of
the mitochondria are normal in structure. There is no intracellular edema.
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Figure 5. Electron microscopic view of the sample of in vitro perfusion control group.
a) I bands b) nucleus of the heart muscle cell c) areas of intracellular edema
d) edematous mitochondria
Edema can be observed in the most of the mitochondria while rupture can be
observed in some. Intracellular edema is present but there is no degeneration in the
general ultrastructure (I bands can be observed).

substances have been studied for myocardial protection
(2-5). Our research was performed using the
Langendorff technique, and the isolated heart was
perfused using ATP-MgCl2 at a certain pressure and flow
level.
It was reported that magnesium is commonly
employed for the treatment of cardiovascular diseases
and that decreases in intracellular and extracellular
magnesium levels may lead to several problems such as
hypertension, congestive heart failure and arrhythmias
due to myocardial infarction (15,16). The findings of our
study performed using ATP-MgCl2 in an in vitro system
show that magnesium can be used in many cardiovascular
diseases related with ischemia-reperfusion injury because
of its ability to improve the hemodynamic parameters, as
stated by previous studies. Thus, the findings of our study
are parallel to the previous findings on this topic.
Pearson et al. (18) showed that hypomagnesemia
distorts NO release from the coronary endothelia in a dog
model. Dickens et al. (19) proved that, in the case of
magnesium deficiency, those tissues exposed to oxidative
stress are extremely damaged as a result of cellular lipid
peroxidation. In a dog gracilis-muscle ischemia454

reperfusion model, it was indicated that superoxide
release from active neutrophils can be decreased with
ATP-MgCl2 and its protective effect is partially based on
this fact (20). In the case of magnesium deficiency,
oxidative damage is increased after the ischemia period,
and this damage can be avoided with the help of
antioxidants (21). With respect to our findings on the
ultrastructure of the study and control groups, no
damage in myofibrillary structure was observed in either
group. However, mitochondrial pathology was evident in
the control group. It was not identified in the ATP-MgCl2
group. We agree with the view expressed by Dickens et
al. (19) that cellular degeneration occurs in
hypomagnesemia.
Magnesium has been investigated for a long time in
relation to organ ischemia and shock. In ischemic injury to
the nerve tissue, the amount of magnesium decreases.
Magnesium improves the microcirculatory distortion
observed in reperfusion, increases the total blood flow to
crucial organs and decreases the cellular edema. It
decreases tissue damage, regulating calcium transport.
The amount of ATP, which decreases during the ischemic
period, increases after the application of magnesium

N. APAYDIN, Z. K. SARITAfi, K. PAMUK, E. ÖZGENC‹L, F. OCAK, T. ULUS, B. BUDAK, S. SÜRÜCÜ, S. F. KATIRCIO⁄LU

treatment (22-24). According to the results of the
ultrastructural analysis of our study, the intracellular
edema observed in the ATP-MgCl2 group was significantly
less than that in the control group. Based on the analysis
of the hemodynamic findings in the ATP-MgCl2 group
during the reperfusion period of our study, it is possible
to argue that magnesium can be applicable during shock.
In our research performed using an isolated rabbit
heart ischemia-reperfusion model, both left ventricle
pressure and dp/dt values were better than those of the

control group. This finding is parallel to the values
determined with an electron microscopic ultrastructural
investigation. ATP-MgCl2, which was proved to be
efficient in various organ ischemia and shock models, was
also efficient in our study (25-26).
In conclusion, the use of ATP-MgCl2 in an in vitro
system is useful for improving hemodynamic and
ultrastructural parameters in ischemia-reperfusion injury.
More comprehensive studies are needed to confirm that
ATP-MgCl2 is a useful medicine in this area.
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